Studies in the Pathogenesis of Systemic Capillary Leak Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

152 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

* Systemic Capillary Leak Syndrome (SCLS) is a disorder of unknown cause characterized by episodes of life-threatening drop in blood pressure and leakage of fluids into tissues. The outcome from an episode of SCLS may be mild and resolve on its own, or may be severe and result in death. Although SCLS likely involves abnormalities in the cells lining blood vessels, the specific cause(s) of this disorder are not known.
* The treatment of choice for an acute SCLS episode is intravenous fluids and drugs such as norepinephrine (adrenaline), which are given to keep blood pressure at a level that will maintain vital organ function. This may be followed by a course of intravenous steroids and IVIG. Currently, there is no cure, but IVIG has been effective in diminishing the frequency and/or intensity of SCLS episodes when given regularly, as long-term effective preventive therapy for many patients who experience recurrent episodes of SCLS.
* This protocol is focused on understanding what causes SCLS with the hope that research findings will lead to the design of safe and more effective treatments.

Objectives:

\- To investigate mechanisms that may cause Systemic Capillary Leak Syndrome.

Eligibility:

* Patients between 16 and older who have been diagnosed with SCLS. Patients who have been diagnosed with SCLS and are between the ages of 7 and 16 may participate off-site, by sending specimens to the NIH. Patients 16 and older who have been diagnosed with SCLS and cannot travel to the NIH may also participate off-site.
* Patients must have a documented history of at least one episode of SCLS with all three of the following documented on at least one occasion: low blood volume, low blood pressure without cause, and evidence of protein leakage during the episode. A letter of a referral from a treating physician is also required.

Design:

* Patients seen on site will be evaluated at the National Institutes of Health (NIH) for approximately 4 to 5 days on an inpatient basis, and will undergo the following procedures:

* Medical history and physical examination.
* Blood samples for evaluation and research purposes, as well as possible genetic testing.
* Apheresis procedure, if needed, to obtain a larger volume of blood cells for research.
* Bone marrow biopsy, if medically indicated.
* Other medically indicated tests, such as skin tests to check for possible allergic reactions.
* Patients who have a capillary leak episode while at NIH will be treated with the standard of care for treating SCLS.
* Patients will be discharged from the protocol 1 year after the NIH visit.
* Patients participating off-site will be asked to collect and send specimens (such as blood) to the NIH for research purposes and evaluation.
* Unaffected Biological relatives of SCLS patients and Unrelated Normal Volunteers may also enroll on the study. Relatives and Normal Volunteers may be asked to provide research samples for the study, such as skin biopsy and research blood specimens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome

NCT01609426

Idiopathic Nephrotic Syndrome

COMPLETED

The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study

NCT00071903

Pseudotumor Cerebri Cystinosis

COMPLETED

Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome

NCT02382575

Nephrotic Syndrome

UNKNOWN PHASE4

Circadian Rhythm Deregulation in Patients With CAPS

NCT06544018

Cryopyrin Associated Periodic Syndrome Familial Cold Urticaria Muckle-Wells Syndrome +1 more

NOT_YET_RECRUITING NA

Heart and Skeletal Muscle Problems in Neuroacanthocytosis

NCT00007228

Choreatic Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The systemic capillary leak syndrome (SCLS, Clarkson syndrome) is an exceedingly rare disorder of unknown cause characterized by chronic edema or acute transient, severe episodes of hypotension, hypovolemia, and oliguria. Severe edema results from leakage of fluid and macromolecules (200-900 kDa) into tissues. Acute SCLS episodes carry a high morbidity and mortality (25-30%). Fewer than 500 cases have been reported worldwide since 1960, although the disease may be underdiagnosed due to the nonspecific nature of the presenting signs and symptoms and the considerable overlap with other shock syndromes including sepsis, anaphylaxis, and angioedema. Approximately 85% of such individuals have a monoclonal gammopathy of unknown significance (MGUS), but the relationship of this finding to disease pathogenesis is unclear. This protocol will focus on the pathogenesis of SCLS. Subjects with documented episodes of capillary leak will be evaluated in order to correlate both clinical and laboratory features that are typical of SCLS. The goal is to identify biological factors and/or genetic and molecular events that may predispose to SCLS episodes. We plan to enroll up to 270 total subjects in this study, which includes affected subjects, family members, and healthy volunteers. We anticipate that our findings may be a first step toward the development of new targeted therapies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Capillary Leak Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers

healthy volunteers to act as controls.

No interventions assigned to this group

Patients with SCLS

patients who have been diagnosed, or are suspected of having systemic capillary leak syndrome.

No interventions assigned to this group

Relatives

relatives of patients who have systemic capillary leak syndrome.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects with SCLS under 8 years of age are only eligible for components of this protocol that can occur Off Site and samples can be sent to the NIH. All SCLS subjects must be at least 8 years old to participate in any other aspects of this protocol at the NIH.

Subjects with SCLS may enter study while pregnant and remain on study after becoming pregnant. At the discretion of the investigator, some components of this protocol will not occur while subject is pregnant.

Diagnosis or suspected diagnosis of Systemic Capillary Leak Syndrome by a physician or documented history of capillary leak as characterized by one or more of the following:

1. Hypotension (systolic blood pressure typically less than 90 mm Hg or diastolic blood pressure less than 60 mm Hg) or associated symptoms of hypotension (e.g., hypotonia \[collapse\], lightheadedness or syncope, incontinence, increased thirst)
2. Laboratory evidence of hemoconcentration (e.g., hemoglobin levels above the normal range \[typically greater than17 g/dL\], elevated leukocyte counts).
3. Clinical evidence of fluid extravasation (e.g. edema) and/or laboratory evidence of protein extravasation such as serum hypoalbuminemia (less than 3.5 g/dL) either chronically or during an acute hypotensive episode.

Letter of referral, with copies of pertinent medical history and laboratory studies, from prospective study subject s referring physician. Patients may self-refer, but a letter of referral from primary physician is still required.

Willing to donate blood for sample storage to be used for future research.

Willing to donate blood for sample storage to be used for future research.

Relatives must be at least 3 years old.

Healthy volunteers must be at least 18 years old.

Relatives may be pregnant or become pregnant while participating in this protocol. At the discretion of the investigator, some components of this protocol will not occur while subject is pregnant. No skin biopsies or intradermal testing will be done on pregnant relatives. Bloodwork volumes may be decreased at the discretion of the investigator.

Healthy volunteers may not be pregnant.

Able to give informed consent.

Exclusion Criteria

Presence of conditions which, in the judgment of the investigator or the referring physician, may put the subject at undue risk for travel (including frequent episodes of severe capillary leak, symptoms not preventable by pre-medication, acute infection, severe thrombocytopenia \[minimum platelet count of 30,000/(proportionaly)L\], or significant cardiovascular disease)

Any condition that in the view of the principal investigator would make the subject unsuitable for enrollment in this study, (i.e. medically unstable, unable to provide phlebotomy samples).

There is an identified cause for hypotensive episodes and/or tissue swelling.

Presence of conditions which in the judgment of the investigator or the referring physician may put the subject at undue risk (i.e. medically unstable, unable to provide phlebotomy samples).

Any condition that in the view of the principal investigator would make the subject unsuitable for enrollment in this study (i.e. medically unstable, unable to provide phlebotomy samples).

Minimum Eligible Age

1 Day

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No